Welcome to our dedicated page for Acadia Healthcar SEC filings (Ticker: ACHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Acadia Healthcare Company, Inc. (NASDAQ: ACHC), a behavioral healthcare company whose subsidiaries own and operate inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, comprehensive treatment centers and outpatient clinics across the United States and Puerto Rico. These regulatory documents offer detailed information about Acadia’s operations, financial performance, governance and material events.
Acadia’s periodic reports and current reports on Form 8-K disclose items such as quarterly and annual financial results, guidance updates, executive appointments and departures, capital expenditure plans and bed growth expectations. For example, 8-K filings have reported the company’s quarterly results, preliminary guidance for future capital expenditures and bed additions, and changes in senior leadership roles, including the appointment of a new Chief Financial Officer and the resignation of the Chief Operating Officer.
Other 8-K filings describe material legal and financial developments, such as the settlement of previously disclosed securities litigation in the United States District Court for the Middle District of Tennessee. In that filing, Acadia outlined the monetary terms of the settlement, the absence of any admission or finding of liability, and its intention to fund the settlement through anticipated insurance proceeds, cash on hand and existing credit lines. Filings also discuss professional and general liability reserves and their impact on the company’s financial outlook.
On Stock Titan, Acadia’s SEC filings are updated as they are made available through EDGAR. AI-powered summaries highlight key points from lengthy documents, helping users quickly understand items such as earnings releases, guidance revisions, executive compensation arrangements, transition and employment agreements, and other governance-related disclosures. Users can also review insider and executive-related information contained in relevant filings to better understand management changes and contractual terms.
Acadia Healthcare Co Inc: The Vanguard Group filed an amended Schedule 13G/A reporting that, following an internal realignment, certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538. The amendment states 0 shares beneficially owned of Acadia Healthcare common stock as reported in the filing dated 03/13/2026.
The filing explains the realignment occurred on January 12, 2026 and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries; it is signed by Ashley Grim on 03/26/2026.
Acadia Healthcare Company, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 6, 2026, in Franklin, Tennessee. Stockholders of record at the close of business on March 9, 2026, may vote, with 92,034,218 shares of common stock outstanding.
Key items include electing three Class III directors to terms expiring in 2029 as part of a phased declassification of the Board, approving a second amendment to the Amended and Restated Incentive Compensation Plan, a non-binding advisory vote on executive compensation, and ratifying Ernst & Young LLP as independent auditor for 2026.
The incentive plan amendment would increase the aggregate number of shares available for issuance or use under the plan by 3,000,000 shares, from 15,175,000 to 18,175,000, supporting equity and cash-based awards for approximately 25,000 employees, officers, consultants and advisors and nine non-employee directors.
The proxy also describes Acadia’s governance structure, committee composition, majority voting and director resignation policies, risk oversight, and a pay-for-performance executive compensation program that emphasizes performance-based cash incentives and a mix of time- and performance-vesting equity awards.
Cancelmi Daniel J reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Daniel J. Cancelmi received a grant of 6,625 shares of common stock as equity compensation. The shares were awarded at no cash cost and are held directly. They will vest over a three-year period in equal annual installments beginning on March 12, 2027, so Cancelmi must remain eligible over time to receive the full amount. Following this grant, he holds 6,625 shares of Acadia Healthcare common stock.
Acadia Healthcare Company, Inc. director Daniel J. Cancelmi filed an initial ownership report on Form 3 for the company’s common stock. The filing shows a direct holding entry with total common shares beneficially owned following the reported date stated as 0.0000 shares.
Acadia Healthcare Company, Inc. announced board changes involving the retirement of one director and the appointment of another experienced healthcare finance executive. Wade D. Miquelon will retire from the Board at the 2026 annual meeting and will not stand for re-election, with the company stating his decision did not result from any disagreement regarding operations, policies or practices.
The Board expanded from 10 to 11 members and appointed Daniel Cancelmi as a Class III director and member of the Audit Committee, effective immediately, with his term running until the 2026 annual meeting. Following Mr. Miquelon’s retirement, the Board size will revert to 10 members as the number of Class III directors decreases from four to three. The company highlighted Mr. Cancelmi’s long-tenured leadership at Tenet Healthcare and broader healthcare finance experience, and noted there are no special appointment arrangements, family relationships or related-party transactions requiring disclosure.
Acadia Healthcare Company, Inc. — The Khrom reporting group amended its Schedule 13D disclosing aggregate beneficial ownership of 7,457,311 Shares of Common Stock as of March 10, 2026, representing approximately 8.09% of outstanding shares.
The filing states Khrom Investments directly holds 7,450,383 Shares, Khrom Capital has shared voting and dispositive power over those same 7,450,383 Shares, and Eric Khrom directly holds 6,928 Shares, for an aggregate total of 7,457,311 Shares. The outstanding share base cited is 92,211,777 Shares as of February 25, 2026 per the Issuer's Annual Report on Form 10-K.
Acadia Healthcare Company, Inc. executive Brian Farley reported a Form 4 showing a tax-related share disposition. On this date, he disposed of 1,915 shares of common stock at a price of $22.29 per share to cover tax withholding obligations, leaving him with 69,165 shares held directly.
Acadia Healthcare Company, Inc. reports full-year 2025 revenue of $3,312.8 million, up from $3,154.0 million, reflecting growth across its behavioral health platform. The company operated 277 facilities with over 12,500 beds in 40 states and Puerto Rico as of December 31, 2025.
Acadia’s revenue mix is diversified, with 57.7% from Medicaid, 24.6% from commercial payors, 14.3% from Medicare and 3.4% from other payors, and no single facility exceeding 4% of revenue. The business focuses on acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers and residential treatment centers.
During 2025, Acadia refinanced its capital structure with a new $1.0 billion senior secured revolving credit facility and a $650.0 million term loan maturing in 2030, and issued $550.0 million of 7.375% senior notes due 2033. Management highlights adequate covenant headroom and maintenance capital expenditures of about 3% of revenue.
Acadia Healthcare reported fourth quarter 2025 revenue of $821.5 million, up 6.1%, but posted a net loss of $1.18 billion versus net income of $33.5 million a year earlier, driven largely by a non-cash goodwill impairment of $996.2 million and higher legal and PLGL-related costs.
Adjusted EBITDA fell to $99.8 million from $153.1 million as PLGL expenses rose and a $147 million securities litigation settlement hit results. For full year 2025, revenue grew to $3.31 billion while net loss reached $1.10 billion. For 2026, the company guides to revenue of $3.37–$3.45 billion, adjusted EBITDA of $575–$610 million, and adjusted EPS of $1.30–$1.55, assuming modest same-facility volume and pricing growth and continued startup losses from new facilities.